Pembrolizumab (Keytruda)
3 clinical trials
1 abstract
7 indications
Indication
Colorectal CancerIndication
Pancreatic CancerIndication
Ovarian CancerIndication
Breast CancerIndication
Uterine CancerIndication
Thyroid CancerAbstract
Overlapping and non-overlapping indications for checkpoint inhibitors in the US.Org: Brigham and Women's Hospital, Department of Epidemiology and Biostatistics, University of California, San Francisco, San Francisco, CA, Memorial Sloan Kettering Cancer Center,
Clinical trial
A Phase II Study Using Short-Term Cultured, Autologous Tumor-Infiltrating Lymphocytes Following a Lymphodepleting Regimen in Metastatic Cancers Plus the Administration of PembrolizumabStatus: Recruiting, Estimated PCD: 2024-12-27
Clinical trial
Neo-adjuvant Pembrolizumab in dMMR/ POLE-EDM Uterine Cancer Patients: a Feasibility StudyStatus: Completed, Estimated PCD: 2023-04-17
Clinical trial
Phase II Trial of Pembrolizumab in Metastatic or Locally Advanced Anaplastic/Undifferentiated Thyroid CancerStatus: Recruiting, Estimated PCD: 2024-11-01